---
name: ‡∏õ‡∏£‡∏∞‡∏Å‡∏≤‡∏®‡∏™‡∏†‡∏≤‡∏Å‡∏≤‡∏£‡∏û‡∏¢‡∏≤‡∏ö‡∏≤‡∏• ‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á ‡∏´‡πâ‡∏≤‡∏°‡∏°‡∏¥‡πÉ‡∏´‡πâ‡∏¢‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠‡∏™‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏ï‡∏£‡∏ß‡∏à‡∏ó‡∏≤‡∏á‡∏£‡∏±‡∏á‡∏™‡∏µ‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤
date: '2023-11-27'
category: ‡∏á ‡∏û‡∏¥‡πÄ‡∏®‡∏©
volume: 140
section: 298
page: 69
source: 'https://ratchakitcha.soc.go.th/documents/11849.pdf'
draft: true
---

# ‡∏õ‡∏£‡∏∞‡∏Å‡∏≤‡∏®‡∏™‡∏†‡∏≤‡∏Å‡∏≤‡∏£‡∏û‡∏¢‡∏≤‡∏ö‡∏≤‡∏• ‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á ‡∏´‡πâ‡∏≤‡∏°‡∏°‡∏¥‡πÉ‡∏´‡πâ‡∏¢‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠‡∏™‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏ï‡∏£‡∏ß‡∏à‡∏ó‡∏≤‡∏á‡∏£‡∏±‡∏á‡∏™‡∏µ‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤

'/2402,44/*.4&41 N/AP/ ‡∏´O4-->Q‡∏´O.4 ‡∏´/A/24/#?PQOQ%4/!//#4/32?/>#.4 /403./‡πç4%4!4-‡∏Ñ/4-Q%O/ d . _ O12 d . ` O‡∏´NO/&3‡∏Ñ3&2,44/*.4&41 /N4 O /.O/‡πç43 O12NAP/%RQ%4/'/2/&/>4?*4/*.4&41O124/( B ‡∏Ñ//,‡πå * . 0 . `cdb 2,44/*.4&41 P .‡∏Ñ/4-N‡∏´O%/&/‡∏Ñ2//-4/2,44/*.4&41Q%4/'/2B-‡∏Ñ/3Q#?P _^ / `cdd N-AP//3%#?P _e !B14‡∏Ñ- `cdd @//'/240R/O 3 !N/R'%?Q O/ _ (CO'/2/&/>4?*4/*.4&41 3Q%‡∏´%@P (CO'/2/&/>4?*4/( B ‡∏Ñ//,‡πå 3Q%‡∏´%@P ‡∏´/A/(CO'/2/&/>4?*4/*.4&41O124/( B ‡∏Ñ//,‡πå 3Q%‡∏´%@P ‡∏´O4-->Q‡∏´O.4‡∏´/A/24/#?PQOQ%4/!//#4/32?/>#.4 #4N/#4 3 !N/R'%?Q _ . _ N/#4#?P‡∏´O4-'>&3!> _ ) N///&N.AP/&BR23%‡∏´13 (epidural space) ` ) N/%Q‡πç4R23%‡∏´13 (subarachnoid space) a ) N/N.AP/‡∏´BO-'/ b ) N/#4‡∏´1/ N1A/ ‡πç 42N/%14 N/O%O!N (CO'/2/&/>4?*N///- R O N'‡∏¥ ‡∏´1/ N1A/ ‡πç 42N/%14 (Central Catheter line) ‡∏´/A/24.2/%‡∏´1/ N1A/ ‡πç 42N/%14 P .(N4%#4‡∏´1/ N1A/ ‡πç 42N/%'14. (Peripherally Inserted Central Catheter (PICC line) R/OO1O/ c ) N//AP% N !4-#?P2,44/*.4&41'/240‡πç4‡∏´% _ . ` 1BN-.4O1224/#?P‡∏´O4-'>&3!> _ ) .4/23&‡∏Ñ/4-/CO2@#?PQ‡∏´O#4‡∏´1/ N1A/ ‡πç 4 (Intravenous anesthetic agents) R O ON R$P/N*O%#31 PN ? .- (Thiopental sodium) ‡∏Ñ?!4-?% R0P /‡∏Ñ1/R/ ‡πå (Ketamine hydrochloride) *//P*+/1 (Propofol) N/P#-?N # (Etomidate) N/O%O!N (CO'/2/&/>4?* 4/*.4&41 3Q%‡∏´%@P ‡∏´/A/(CO'/2/&/>4?*4/*.4&41O124/( B ‡∏Ñ//,‡πå 3Q%‡∏´%@P #?P(N4%4//&/- />23‡∏ç‡∏ç?*.4&41 #3Q%?Q 4/'>&3!>4%//>23‡∏ç‡∏ç?*.4&41Q%2"4%*.4&41233 /2#// #&/ /- /BN#*-‡∏´4%‡∏Ñ/ N-A/*3#.4 /‡∏Ñ‡πå4/&/>‡∏´4/2N/%3‡∏´/3 N#0&41 2B4,>&41 /‡∏Ñ‡πå4/&/>‡∏´4/ 2N/%#O/">P%‡∏´/A/2,444 R#. Q‡∏´O'>&3!>4%Q%‡∏´O/(N4!3 ‡∏´/A/%/‡∏´O/(N4!3 R O !4-‡∏Ñ/4-‡πç4N'‡πá% P .!O//.CNQ%‡∏Ñ/4-‡∏Ñ/&‡∏ÑB-//>23‡∏ç‡∏ç?O*#.‡πå‡∏´/A/(CO'/2/&/>4?*N///-#?P'>&3!>4%/N/- O /.  2%3Q% 4/'>&3!>4%//>23‡∏ç‡∏ç?*.4&41Q%2"4%*.4&41!4-*/2/4&3‡∏ç‡∏ç3!> 2"4%*.4&41 * . 0 . `cb_ Q‡∏´O'>&3!>4%Q%‡∏´O/(N4!3 P .!O//.CNQ%‡∏Ñ/4-‡∏Ñ/&‡∏ÑB-//>23‡∏ç‡∏ç?O*#.‡πå ` ) 1BN-.4 Hazardous N/O%O!NR O '>&3!>!4-O/ ` ‡∏´‡∏ô‡πâ‡∏≤ 69 ‡πÄ‡∏•Ôúä‡∏° 140 ‡∏ï‡∏≠‡∏ô‡∏û‡∏¥‡πÄ‡∏®‡∏© 298 ‡∏á ‡∏£‡∏≤‡∏ä‡∏Å‡∏¥‡∏à‡∏à‡∏≤‡∏ô‡∏∏‡πÄ‡∏ö‡∏Å‡∏©‡∏≤ 27 ‡∏û‡∏§‡∏®‡∏à‡∏¥‡∏Å‡∏≤‡∏¢‡∏ô 2566

a ) 1BN-24/#?PQOQ%4/!//#4/32?/>#.4 24/#@&/32? (Contrast Media) 24/N,23/32?2‡πç4‡∏´/3&4/!///>%>3. (Diagnostic Radiopharmaceuticals) N/O%O!NR O '>&3!>!4-O/ a O/ ` (CO'/2/&/>4?*4/*.4&41 3Q%‡∏´%@P ‡∏´/A/(CO'/2/&/>4?*4/*.4&41 O124/( B ‡∏Ñ//,‡πå 3Q%‡∏´%@P /4Q‡∏´O.41BN- Hazardous R O Q%/? 3 !N/R'%?Q 1) 1BN-.4 Cytotoxic ( N‡∏Ñ-?&‡πç4&3 ) !O/(N4%‡∏´132C!/4/)‡∏∂/&/-/2.223Q% 2444/*.4&41(CO'N/.-2N/O#?PR O /3&.4N‡∏Ñ-?&‡πç4&3 #?P2,44/*.4&41'/240‡πç4‡∏´% O12R O /3& ‡∏´%32A//3&//42,44/*.4&41 2) 1BN-.4 Non-Cytotoxic NN% Monoclonal antibody/Immunotherapy !O/(N4%4//&/-‡∏Ñ/4-/COO12#312Q%4/QO.41BN-%?Q 3) 1BN-.4 Hazardous !O/R O /3&4/N!/?.- ‡∏´/A/(2-N/?.&/O/.O1O/ P .(CO#?P-?‡∏´%O4#?P/3&(> /& N/O%O!N.4%3Q%/.CNQ%/C'O&&*/O/-QO4% ‡∏´O4-(CO'/2/&/>4?*4/*.4&41 3Q%‡∏´%@P ‡∏´/A/(CO'/2/&/>4?*4/*.4&41O124/( B ‡∏Ñ//,‡πå 3Q%‡∏´%@P N'‡πá%(CON!/?.-‡∏´/A/(2-.4 4) N/#44/Q‡∏´O.41BN- Hazardous 24-4/"Q‡∏´OR O #BN/#4 N/O%O!NN/#4 #?P‡πç4‡∏´% ‡∏´O4-R/OQ%O/ _ . _ #3Q%?Q 4/'>&3!>4% 3 1N4/ !O//.CN,4.Q!OO(%4//314/(CO'/2/&/>4?*N///- O/ a (CO'/2/&/>4?*4/*.4&41 3Q%‡∏´%@P ‡∏´/A/(CO'/2/&/>4?*4/*.4&41 O124/( B ‡∏Ñ//,‡πå 3Q%‡∏´%@P /4Q‡∏´O1BN-24/#?PQOQ%4/!//#4/32?/>#.4 24/#@&/32? (Contrast Media) 24/N,23/32?2‡πç4‡∏´/3&4/!///>%>3. (Diagnostic Radiopharmaceuticals) R O Q%/? 3 !N/R'%?Q 1) !O/(N4%‡∏´132C!/)‡∏∂/&/-4/*.4&41N*42#4 2444/*.4&41/32?/>#.4 ‡∏´/A/‡∏´132C!/4/*.4&41/32?/>#.4N*42244 !4-#?P2,44/*.4&41'/240‡πç4‡∏´% O12R O /3& ‡∏´%32A//3&//42,44/*.4&41 2) 24/1 #?PQO R O -?4/N!/?.- ‡∏´/A/(2-N/?.&/O/.O1O/ P .(CO#?P-?‡∏´%O4#?P/3&(> /& N/O%O!N24/%3Q%/.CNQ%/C'O&&*/O/-QO4% ‡∏´O4-(CO'/2/&/>4?*4/*.4&41 3Q%‡∏´%@P ‡∏´/A/(CO'/2/&/>4?* 4/*.4&41O124/( B ‡∏Ñ//,‡πå 3Q%‡∏´%@P N'‡πá%(CON!/?.-‡∏´/A/(2-24/1 3) N/#44/Q‡∏´O24/1 24-4/"Q‡∏´OR O #BN/#4N/O%O!NN/#4#?P‡πç4‡∏´% ‡∏´O4-R/O Q%O/ _ . _ #3Q%?Q 4/'>&3!>4% 3 1N4/ !O//.CNQ%‡∏Ñ/4-‡∏Ñ/&‡∏ÑB-//32?O*#.‡πå‡∏´/A/(CO'/2/&/>4?*N///- #?P'>&3!>4%/N/- O /.  2%3Q% ‡∏´‡∏ô‡πâ‡∏≤ 70 ‡πÄ‡∏•Ôúä‡∏° 140 ‡∏ï‡∏≠‡∏ô‡∏û‡∏¥‡πÄ‡∏®‡∏© 298 ‡∏á ‡∏£‡∏≤‡∏ä‡∏Å‡∏¥‡∏à‡∏à‡∏≤‡∏ô‡∏∏‡πÄ‡∏ö‡∏Å‡∏©‡∏≤ 27 ‡∏û‡∏§‡∏®‡∏à‡∏¥‡∏Å‡∏≤‡∏¢‡∏ô 2566

O/ b N*AP/Q‡∏´O4/&/>4/O4!O%-?‡∏Ñ/4-'1/ ,3.#3Q(CO/3&&/>4/ (COQ‡∏´O&/>4/ O122>PO/ 1O/- 2"4%&/>4/!O/3 Q‡∏´O-?O%/#44/'>&3!>4%#?PR O -4!/4% 3 Q‡∏´O-?/B'/‡πå'O/3%Q‡∏´O‡∏Ñ/&"O/% !4--4!/4% 2%3&2%B%Q‡∏´O-?4/*3%4‡∏Ñ/4-/COO12#312/(COQ‡∏´O&/>4//.N4!N/N%AP/ '/240&3&%?QQ‡∏´OQO&3‡∏Ñ3&!3QO!N/3%"3 4/3%'/240Q%/4>4%BN&14N'‡πá%!O%R' '/240  /3%#?P 1 *00>4.% * . 0 . `c 66 //042!/44/.‡πå2B>!/4 N‡∏´1A//-/N1>0 %4.2,44/*.4&41 ‡∏´‡∏ô‡πâ‡∏≤ 71 ‡πÄ‡∏•Ôúä‡∏° 140 ‡∏ï‡∏≠‡∏ô‡∏û‡∏¥‡πÄ‡∏®‡∏© 298 ‡∏á ‡∏£‡∏≤‡∏ä‡∏Å‡∏¥‡∏à‡∏à‡∏≤‡∏ô‡∏∏‡πÄ‡∏ö‡∏Å‡∏©‡∏≤ 27 ‡∏û‡∏§‡∏®‡∏à‡∏¥‡∏Å‡∏≤‡∏¢‡∏ô 2566 Powered by TCPDF (www.tcpdf.org)
